Prostate cancer
Pro Research Analysisby 
Searched over 200M research papers for "prostate cancer"
Prostate Cancer Epidemiology and Risk Factors
Prostate cancer is the second most common cancer in men worldwide and a leading cause of cancer-related death, particularly in developed countries and among men of African descent, who are at higher risk and often present with more aggressive disease 359. Age, family history, and genetic mutations such as BRCA1/2 are significant risk factors, with incidence increasing sharply in men over 65 years old 359. Obesity is also associated with increased risk . The widespread use of prostate-specific antigen (PSA) testing has led to higher reported incidence rates, but also to concerns about overdiagnosis and overtreatment, as many detected cancers may remain asymptomatic throughout a patient’s life 359.
Diagnosis and Staging of Prostate Cancer
Prostate cancer is typically diagnosed through a combination of PSA blood testing, digital rectal examination, and confirmatory prostate biopsy 156. The Gleason scoring system, combined with clinical staging, is used to assess prognosis and guide treatment decisions . Advances in imaging have improved diagnostic accuracy and staging, allowing for better surveillance and management strategies 27.
Genetic and Molecular Features
Key genetic alterations in prostate cancer include fusions of TMPRSS2 with ETS family genes, MYC oncogene amplification, and mutations or deletions in PTEN and TP53. In advanced disease, androgen receptor (AR) amplification or mutation is common . Recent research has identified both rare high-risk mutations (e.g., BRCA2, HOXB13) and common low-risk alleles, which may enable more targeted screening and personalized management in the future . Molecular subtyping, such as ETS-gene-fusion-positive and SPINK1-overexpressing cancers, is helping to stratify patients for different treatment approaches .
Treatment Approaches for Localized and Advanced Disease
For localized, low- to intermediate-risk prostate cancer, active surveillance, radical prostatectomy (often robotic), and ablative radiotherapy are standard curative options, with a 10-year overall survival rate of about 99% if detected early 156. National guidelines have become more conservative, recommending observation or watchful waiting for older men with low-risk disease to avoid overtreatment .
In higher-risk or advanced cases, androgen deprivation therapy (ADT) is commonly used, often followed by next-generation endocrine therapies such as enzalutamide or abiraterone, and sometimes combined with chemotherapy (e.g., docetaxel) 158. Despite initial responses, most advanced cancers eventually progress to a castration-resistant state, which is considered incurable 134. For metastatic disease, aggressive management of the primary tumor and metastasis-directed therapies are being evaluated, and novel AR pathway inhibitors have improved survival when used as first-line therapy .
Emerging and Targeted Therapies
Recent advances include the use of PARP inhibitors (e.g., olaparib) for patients with DNA repair gene mutations, targeted radioisotopes (e.g., radium-223 for bone metastases), and immunotherapies such as pembrolizumab for specific molecular subtypes 1258. The therapeutic landscape is rapidly evolving, with ongoing research into optimal drug sequencing and patient selection for these newer agents 48.
Screening, Prevention, and Future Directions
Screening for prostate cancer remains controversial due to the risk of overdiagnosis and unnecessary biopsies, though it can reduce mortality in some populations 459. Lifestyle modifications, such as reducing high-fat foods, increasing fruit and vegetable intake, and regular exercise, may help lower risk, but no definitive preventive measures have been established . Ongoing research aims to further personalize management, improve early detection, and develop more effective treatments for all stages of prostate cancer 1247.
Conclusion
Prostate cancer is a complex and heterogeneous disease with significant advances in diagnosis, molecular understanding, and treatment over recent years. While early-stage disease has excellent outcomes, advanced and castration-resistant prostate cancer remain challenging. Continued research and personalized approaches are essential to further improve patient outcomes and quality of life 1247+1 MORE.
Sources and full results
Most relevant research papers on this topic